TARGET AUDIENCE

Hematologists/oncologists, nurses, nurse practitioners (NPs), pharmacists, and other healthcare professionals (HCPs) involved in the care of patients with hematological malignancies and disorders.

LEARNING OBJECTIVES

Upon completion of this activity, learners will have: [LIST] [ITEM]Increased knowledge regarding the: [LIST] [ITEM]Emerging clinical trial data for hematologic malignancies [ITEM]Methods to assess treatment response in patients with hematologic malignancies and disorders [ITEM]Treatment-related adverse events of agents used for hematologic malignancies and disorders [/LIST] [ITEM]Greater confidence in their ability to individualize treatment for patients with hematologic malignancies and disorders [/LIST]

ACCREDITATION STATEMENTS

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. [JALOGO][MEDSCAPE]

[bold]For Full Conference Attendance:[/bold] [bold]For Physicians[/bold] Medscape, LLC designates this other activity for a maximum of [bold]6.75[/bold][italic] AMA PRA Category 1 Credit(s)™. [/italic]Physicians should claim only the credit commensurate with the extent of their participation in the activity. [bold]For Nurses [/bold] Awarded 6.75 contact hour(s) of nursing continuing professional development for RNs and APNs; pending hours of nursing pharmacology content. [bold]For Pharmacists [/bold] Medscape designates this continuing education activity for 6.75 Knowledge-based contact hours (0.675 CEUs). (UANs for pharmacy credits to appear in final conference materials)